The total number of records retrieved from this search are 92. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_1097	Virus nameAdenovirus	Virus strainZD55-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAdenovirus expressing ZD55 gene and IL-24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeExpressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman cervical carcinoma cell line	Cell lineSW620	Concentration of cell line2.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro resultNo cell killing after 80 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15661558
IDOV_1098	Virus nameAdenovirus	Virus strainAd-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAdenovirus expressing IL-24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeExpressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman cervical carcinoma cell line	Cell lineSW620	Concentration of cell line2.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro resultNo cell killing after 80 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15661558
IDOV_1099	Virus nameAdenovirus	Virus strainZD55-EGFP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAdenovirus expressing EGFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman cervical carcinoma cell line	Cell lineSW620	Concentration of cell line2.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro resultNo cell killing after 80 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15661558
IDOV_1150	Virus nameHerpes simplex virus	Virus strainNV1020	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineColon carcinoma cell line	Cell lineSW620	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayWST-1 assay	In-vitro virus concentration1 × 10⁶ pfu/ml	In-vitro result80% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17117895
IDOV_2073	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of shMPP1 expressing cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.1 MOI	In-vitro resultNo cell death observed	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of senescence	Immunogenic effectNA	Clinical trialNA	PMID21794078
IDOV_2074	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of shMPP1 expressing cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration1 MOI	In-vitro resultSome cell death observed	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of senescence	Immunogenic effectNA	Clinical trialNA	PMID21794078
IDOV_2075	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of shMPP1 expressing cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro resultAll cells was dead	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of senescence	Immunogenic effectNA	Clinical trialNA	PMID21794078
IDOV_2076	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of shMPP1 expressing cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration100 MOI	In-vitro resultAll cells was dead	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21794078
IDOV_2089	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of shMPP1 expressing cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro resultAbsorbance decrease to below 0.1 after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21794078
IDOV_2090	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of shMPP1 expressing cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro resultAbsorbance decrease to below 0.1 after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21794078
IDOV_2091	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of shMPP1 expressing cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro resultAbsorbance decrease to below 0.1 after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21794078
IDOV_2092	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of shMPP1 expressing cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro resultAbsorbance decrease to below 0.1 after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21794078
IDOV_2093	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of shMPP1 expressing cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for SW620 cell line (5.0E+6 cells)	In-vivo virus concentration2.0E+9 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume below 100 mm after 9 weeks	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21794078
IDOV_2102	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of AFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.1 MOI	In-vitro resultNo cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID21979578
IDOV_2103	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of AFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration1 MOI	In-vitro resultNo cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID21979578
IDOV_2104	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of AFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro resultNo cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID21979578
IDOV_2105	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of AFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration100 MOI	In-vitro resultNo cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID21979578
IDOV_2122	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of TRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.1 MOI	In-vitro resultSome cell death observed	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID21979578
IDOV_2123	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of TRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration1 MOI	In-vitro resultSome cell death observed	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID21979578
IDOV_2124	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of TRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro resultSome cell death observed	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID21979578
IDOV_2125	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of TRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration100 MOI	In-vitro resultSome cell death observed	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID21979578
IDOV_2159	Virus nameEnterovirus	Virus strainEnterovirus B species echovirus 12	Virus genome typeRNA	Virus familyPicornaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineColon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayMicroscopy examination	In-vitro virus concentration1 MOI	In-vitro resultComplete cell death after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus can cause induction in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21999585
IDOV_2160	Virus nameEnterovirus	Virus strainEnterovirus B species echovirus 15	Virus genome typeRNA	Virus familyPicornaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineColon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayMicroscopy examination	In-vitro virus concentration1 MOI	In-vitro resultComplete cell death after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus can cause induction in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21999585
IDOV_2161	Virus nameEnterovirus	Virus strainEnterovirus B species echovirus 17	Virus genome typeRNA	Virus familyPicornaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineColon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayMicroscopy examination	In-vitro virus concentration1 MOI	In-vitro resultComplete cell death after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus can cause induction in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21999585
IDOV_2162	Virus nameEnterovirus	Virus strainEnterovirus B species echovirus 26	Virus genome typeRNA	Virus familyPicornaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineColon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayMicroscopy examination	In-vitro virus concentration1 MOI	In-vitro resultComplete cell death after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus can cause induction in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21999585
IDOV_2163	Virus nameEnterovirus	Virus strainEnterovirus B species echovirus 29	Virus genome typeRNA	Virus familyPicornaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineColon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayMicroscopy examination	In-vitro virus concentration1 MOI	In-vitro resultComplete cell death after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus can cause induction in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21999585
IDOV_2756	Virus nameAdenovirus	Virus strainZD55-lipocalin2	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B55 gene and insertion of lipocalin2 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro resultNo cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInducing apoptosis and decreasing microvessel density of tumor	Immunogenic effectNA	Clinical trialNA	PMID23464854
IDOV_2757	Virus nameAdenovirus	Virus strainZD55-lipocalin2	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B55 gene and insertion of lipocalin2 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro resultModerate cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInducing apoptosis and decreasing microvessel density of tumor	Immunogenic effectNA	Clinical trialNA	PMID23464854
IDOV_2758	Virus nameAdenovirus	Virus strainZD55-lipocalin2	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B55 gene and insertion of lipocalin2 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro resultMost of the cells are died	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInducing apoptosis and decreasing microvessel density of tumor	Immunogenic effectNA	Clinical trialNA	PMID23464854
IDOV_2759	Virus nameAdenovirus	Virus strainZD55-lipocalin2	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B55 gene and insertion of lipocalin2 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro resultAll cells are died	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInducing apoptosis and decreasing microvessel density of tumor	Immunogenic effectNA	Clinical trialNA	PMID23464854
IDOV_2768	Virus nameAdenovirus	Virus strainZD55-lipocalin2	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B55 gene and insertion of lipocalin2 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismnude mice xenograft for Sw620 (1.5E+7 cells)	In-vivo virus concentration5.0E+8 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume below 500 as comapred to control 1500mm and increase in median survival time	Mode of deliveryIntratumoral	Pathway inducedInducing apoptosis and decreasing microvessel density of tumor	Immunogenic effectNA	Clinical trialNA	PMID23464854
IDOV_2822	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectUpregulation of immune related antigens and cytokines like IFN-gamma, IP-10, MCP-1, MCP-3	Clinical trialNA	PMID23531320
IDOV_2823	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result90% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectUpregulation of immune related antigens and cytokines like IFN-gamma, IP-10, MCP-1, MCP-3	Clinical trialNA	PMID23531320
IDOV_2824	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result50% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectUpregulation of immune related antigens and cytokines like IFN-gamma, IP-10, MCP-1, MCP-3	Clinical trialNA	PMID23531320
IDOV_2837	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result80% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectUpregulation of immune related antigens and cytokines like IFN-gamma, IP-10, MCP-1, MCP-3	Clinical trialNA	PMID23531320
IDOV_2838	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result40% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectUpregulation of immune related antigens and cytokines like IFN-gamma, IP-10, MCP-1, MCP-3	Clinical trialNA	PMID23531320
IDOV_2839	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectUpregulation of immune related antigens and cytokines like IFN-gamma, IP-10, MCP-1, MCP-3	Clinical trialNA	PMID23531320
IDOV_2851	Virus nameMeasles virus	Virus strainAttenuated strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineLaboratory grown own culture	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayCell death detection kit	In-vitro virus concentration1 MOI	In-vitro result30% cells survived	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of caspase-3	Immunogenic effectNA	Clinical trialNA	PMID23586034
IDOV_3141	Virus nameHerpes simplex virus	Virus strainSPDD-UG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressing SNORD44 gene and GAS5 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell bank of type culture collection of chinese academy of science	Origin of cell lineHuman colon carcinoma cell line	Cell lineSW620	Concentration of cell line2000 cells per well	In-vitro toxicityNA	AssayCCK-8 assay	In-vitro virus concentration5 MOI	In-vitro result50% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase dependent Induction of apoptosis as measured by TUNEL assay in both tumor model and cell line	Immunogenic effectNA	Clinical trialNA	PMID28530127
IDOV_3142	Virus nameHerpes simplex virus	Virus strainSPDD-UG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressing SNORD44 gene and GAS5 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell bank of type culture collection of chinese academy of science	Origin of cell lineHuman colon carcinoma cell line	Cell lineSW620	Concentration of cell line2000 cells per well	In-vitro toxicityNA	AssayCCK-8 assay	In-vitro virus concentration10 MOI	In-vitro result25% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase dependent Induction of apoptosis as measured by TUNEL assay in both tumor model and cell line	Immunogenic effectNA	Clinical trialNA	PMID28530127
IDOV_3143	Virus nameHerpes simplex virus	Virus strainSPDD-UG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressing SNORD44 gene and GAS5 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell bank of type culture collection of chinese academy of science	Origin of cell lineHuman colon carcinoma cell line	Cell lineSW620	Concentration of cell line2000 cells per well	In-vitro toxicityNA	AssayCCK-8 assay	In-vitro virus concentration20 MOI	In-vitro result18% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase dependent Induction of apoptosis as measured by TUNEL assay in both tumor model and cell line	Immunogenic effectNA	Clinical trialNA	PMID28530127
IDOV_3147	Virus nameHerpes simplex virus	Virus strainSPDD-UG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressing SNORD44 gene and GAS5 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell bank of type culture collection of chinese academy of science	Origin of cell lineHuman colon carcinoma cell line	Cell lineSW620	Concentration of cell line2000 cells per well	In-vitro toxicityNA	AssayCCK-8 assay	In-vitro virus concentration10 MOI	In-vitro result90% cell viability after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase dependent Induction of apoptosis as measured by TUNEL assay in both tumor model and cell line	Immunogenic effectNA	Clinical trialNA	PMID28530127
IDOV_3148	Virus nameHerpes simplex virus	Virus strainSPDD-UG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressing SNORD44 gene and GAS5 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell bank of type culture collection of chinese academy of science	Origin of cell lineHuman colon carcinoma cell line	Cell lineSW620	Concentration of cell line2000 cells per well	In-vitro toxicityNA	AssayCCK-8 assay	In-vitro virus concentration10 MOI	In-vitro result60% cell viability after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase dependent Induction of apoptosis as measured by TUNEL assay in both tumor model and cell line	Immunogenic effectNA	Clinical trialNA	PMID28530127
IDOV_3149	Virus nameHerpes simplex virus	Virus strainSPDD-UG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressing SNORD44 gene and GAS5 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell bank of type culture collection of chinese academy of science	Origin of cell lineHuman colon carcinoma cell line	Cell lineSW620	Concentration of cell line2000 cells per well	In-vitro toxicityNA	AssayCCK-8 assay	In-vitro virus concentration10 MOI	In-vitro result40% cell viability after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase dependent Induction of apoptosis as measured by TUNEL assay in both tumor model and cell line	Immunogenic effectNA	Clinical trialNA	PMID28530127
IDOV_3150	Virus nameHerpes simplex virus	Virus strainSPDD-UG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressing SNORD44 gene and GAS5 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell bank of type culture collection of chinese academy of science	Origin of cell lineHuman colon carcinoma cell line	Cell lineSW620	Concentration of cell line2000 cells per well	In-vitro toxicityNA	AssayCCK-8 assay	In-vitro virus concentration10 MOI	In-vitro result10% cell viability after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase dependent Induction of apoptosis as measured by TUNEL assay in both tumor model and cell line	Immunogenic effectNA	Clinical trialNA	PMID28530127
IDOV_3155	Virus nameHerpes simplex virus	Virus strainSPDD-UG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressing SNORD44 gene and GAS5 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell bank of type culture collection of chinese academy of science	Origin of cell lineHuman colon carcinoma cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismMouse model xenograft for SW620 (1.0E+6)	In-vivo virus concentration5.0E+8 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume below 200mm as compared to control 2500mm after 24 days	Mode of deliveryIntratumoral	Pathway inducedCaspase dependent Induction of apoptosis as measured by TUNEL assay in both tumor model and cell line	Immunogenic effectNA	Clinical trialNA	PMID28530127
IDOV_3157	Virus nameHerpes simplex virus	Virus strainSPDD-UG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressing SNORD44 gene and GAS5 gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with rapamycin (5nM)	Immune gene insertion in viral genomeNo	Source of cell lineCell bank of type culture collection of chinese academy of science	Origin of cell lineHuman colon carcinoma cell line	Cell lineSW620	Concentration of cell line2000 cells per well	In-vitro toxicityNA	AssayCCK-8 assay	In-vitro virus concentration5 MOI	In-vitro result60% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase dependent Induction of apoptosis as measured by TUNEL assay in both tumor model and cell line	Immunogenic effectNA	Clinical trialNA	PMID28530127
IDOV_3158	Virus nameHerpes simplex virus	Virus strainSPDD-UG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressing SNORD44 gene and GAS5 gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with rapamycin (10nM)	Immune gene insertion in viral genomeNo	Source of cell lineCell bank of type culture collection of chinese academy of science	Origin of cell lineHuman colon carcinoma cell line	Cell lineSW620	Concentration of cell line2000 cells per well	In-vitro toxicityNA	AssayCCK-8 assay	In-vitro virus concentration10 MOI	In-vitro result50% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase dependent Induction of apoptosis as measured by TUNEL assay in both tumor model and cell line	Immunogenic effectNA	Clinical trialNA	PMID28530127
IDOV_3159	Virus nameHerpes simplex virus	Virus strainSPDD-UG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressing SNORD44 gene and GAS5 gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with rapamycin (20nM)	Immune gene insertion in viral genomeNo	Source of cell lineCell bank of type culture collection of chinese academy of science	Origin of cell lineHuman colon carcinoma cell line	Cell lineSW620	Concentration of cell line2000 cells per well	In-vitro toxicityNA	AssayCCK-8 assay	In-vitro virus concentration20 MOI	In-vitro result40% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase dependent Induction of apoptosis as measured by TUNEL assay in both tumor model and cell line	Immunogenic effectNA	Clinical trialNA	PMID28530127
IDOV_3298	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 81.1% as compared to control 100% after day 3	Mode of deliveryIntratumoral	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3299	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 89.7% as compared to control 100% after day 5	Mode of deliveryIntratumoral	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3300	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 80.7% as compared to control 100% after day 8	Mode of deliveryIntratumoral	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3301	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 71.9% as compared to control 100% after day 10	Mode of deliveryIntratumoral	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3302	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 68.1% as compared to control 100% after day 12	Mode of deliveryIntratumoral	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3303	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 58.4% as compared to control 100% after day 15	Mode of deliveryIntratumoral	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3304	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 57.1% as compared to control 100% after day 17	Mode of deliveryIntratumoral	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3305	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 58.3% as compared to control 100% after day 19	Mode of deliveryIntratumoral	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3306	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 67.8% as compared to control 100% after day 3	Mode of deliveryIntravenous	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3307	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 60.8% as compared to control 100% after day 5	Mode of deliveryIntravenous	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3308	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 62.4% as compared to control 100% after day 8	Mode of deliveryIntravenous	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3309	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 64.7% as compared to control 100% after day 10	Mode of deliveryIntravenous	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3310	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 64.4% as compared to control 100% after day 12	Mode of deliveryIntravenous	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3311	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 61.5% as compared to control 100% after day 15	Mode of deliveryIntravenous	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3312	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 59.7% as compared to control 100% after day 17	Mode of deliveryIntravenous	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3313	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 59.9% as compared to control 100% after day 19	Mode of deliveryIntravenous	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3546	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result98% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3547	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result90% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3548	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result70% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3549	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result45% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3550	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result98% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3551	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result90% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3552	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result50% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3553	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result25% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3554	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration15 MOI	In-vitro result95% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3555	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration15 MOI	In-vitro result80% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3556	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration15 MOI	In-vitro result40% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3557	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration15 MOI	In-vitro result20% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3558	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with luteolin (25 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result60% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3559	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with luteolin (25 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result18% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3560	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with luteolin (25 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result17% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3561	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with luteolin (25 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro resultComplete cell death after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3562	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with luteolin (25 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result58% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3563	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with luteolin (25 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result16% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3564	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with luteolin (25 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result5% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3565	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with luteolin (25 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro resultComplete cell death after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3566	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with luteolin (25 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration15 MOI	In-vitro result58% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3567	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with luteolin (25 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration15 MOI	In-vitro result16% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3568	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with luteolin (25 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration15 MOI	In-vitro result5% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3569	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with luteolin (25 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineSW620	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration15 MOI	In-vitro resultComplete cell death after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_4291	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal adenocarcinoma	Cell lineSW620	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 pfu	In-vitro result43.7 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_5624	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon carcinoma cell line	Cell lineSW620	Concentration of cell line80% confluency	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration55 pfu	In-vitro result50% of cancer cell death occurs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5844	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon carcinoma cell line	Cell lineSW620	Concentration of cell line80% confluency	In-vitro toxicityNA	AssayNA	In-vitro virus concentration55 pfu	In-vitro result50% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578